Skip to content

Rosetta Genomics Ltd.: 20-F filed 2016-03-23

What Rosetta Genomics Ltd. reported in its annual report (foreign private issuer) filed 2016-03-23 (fiscal FY 2015): 30 published measures, 78 facts as tagged in accession 0001144204-16-089835.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2016-03-23
Fiscal period
fiscal FY 2015
Accession
0001144204-16-089835 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Rosetta Genomics Ltd. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-12-3122,423,000USD
At 2014-12-3117,278,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-12-3112,447,000USD
At 2014-12-317,929,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-17,345,000USD365
2014-01-01 to 2014-12-31-14,526,000USD365
2013-01-01 to 2013-12-31-12,897,000USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-16,933,000USD365
2014-01-01 to 2014-12-31-13,602,000USD365
2013-01-01 to 2013-12-31-10,608,000USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2015-01-01 to 2015-12-31273,000USD365
2014-01-01 to 2014-12-31247,000USD365
2013-01-01 to 2013-12-31626,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-12-31-140,270,000USD
At 2014-12-31-122,925,000USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-01-01 to 2015-12-3119,000USD365
2014-01-01 to 2014-12-3115,000USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-12-312,975,000USD
At 2014-12-31822,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-12-311,016,000USD365
2014-01-01 to 2014-12-31943,000USD365
2013-01-01 to 2013-12-31893,000USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-15,721,000USD365
2014-01-01 to 2014-12-31-14,252,000USD365
2013-01-01 to 2013-12-31-13,347,000USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-12-3119,370,000USD
At 2014-12-3116,452,000USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-01-01 to 2015-12-3148,000USD365
2014-01-01 to 2014-12-3139,000USD365
2013-01-01 to 2013-12-3115,000USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-12-312,803,000USD
At 2014-12-312,211,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2015-12-313,633,000USD
At 2014-12-31338,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-01-01 to 2015-12-3117,717,000USD365
2014-01-01 to 2014-12-3114,269,000USD365
2013-01-01 to 2013-12-3113,043,000USD365

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2015-01-01 to 2015-12-311,996,000USD365
2014-01-01 to 2014-12-3117,000USD365
2013-01-01 to 2013-12-31-304,000USD365

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2015-01-01 to 2015-12-316,272,000USD365
2014-01-01 to 2014-12-311,310,000USD365
2013-01-01 to 2013-12-31709,000USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-01-01 to 2015-12-312,956,000USD365
2014-01-01 to 2014-12-311,927,000USD365
2013-01-01 to 2013-12-311,744,000USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-12-3120,515,536shares
At 2014-12-3111,762,420shares

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2015-12-3119,620,000USD
At 2014-12-3115,065,000USD
At 2013-12-3123,633,000USD
At 2012-12-3130,900,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2015-12-316,052,000USD
At 2014-12-313,151,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2015-12-313,077,000USD
At 2014-12-312,329,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-12-312,192,000USD
At 2014-12-31483,000USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2015-12-3142,470,000USD
At 2014-12-3134,409,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-17,326,000USD365
2014-01-01 to 2014-12-31-14,511,000USD365
2013-01-01 to 2013-12-31-13,170,000USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-12-317,566,000USD365
2014-01-01 to 2014-12-315,494,000USD365
2013-01-01 to 2013-12-314,297,000USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2015-01-01 to 2015-12-31748,000USD365
2014-01-01 to 2014-12-31299,000USD365
2013-01-01 to 2013-12-31298,000USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-1,605,000USD365
2014-01-01 to 2014-12-31-259,000USD365
2013-01-01 to 2013-12-31177,000USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-12-311,256,000USD365
2014-01-01 to 2014-12-31114,000USD365
2013-01-01 to 2013-12-31136,000USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-12-31101,000USD365
2014-01-01 to 2014-12-31-343,000USD365
2013-01-01 to 2013-12-31152,000USD365

Inspect the source

Entity
Rosetta Genomics Ltd. / CIK 0001362959
Captured
SEC response SHA-256
3d8748a302f8951b081812bc9c273e28f113a24713e84dbd18ed26c2432f02a8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001362959.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))